Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
memantine + methylphenidate
- Development stage
- Preclinical
- Lead developer
- Massachusetts General Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of memantine, an NMDA receptor antagonist, and methylphenidate, a central nervous system stimulant. This combination is being investigated for the treatment of ADHD, particularly for improving executive function deficits. Memantine may amplify the effects of methylphenidate on aspects of emotional self-regulation by regulating both prefrontal glutamate and dopamine activity.
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)DAT (Dopamine plasma membrane transport protein)
Beyond the preview
Go deeper on memantine + methylphenidate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on memantine + methylphenidate.